Valuation: Guerbet

Market Cap 83.89M 94.13M 78.2M 71.19M 134M 9.07B 135M 945M 367M 4.62B 353M 346M 14.86B P/E 2026 *
-3.73x
P/E 2027 * 7.24x
Enterprise Value 459M 516M 428M 390M 735M 49.67B 740M 5.17B 2.01B 25.33B 1.94B 1.89B 81.41B EV / Sales 2026 *
0.6x
EV / Sales 2027 * 0.57x
Free-Float
36.58%
Yield 2026 *
2.51%
Yield 2027 * 3.51%
1 day-3.59%
1 week-5.80%
Current month-12.23%
1 month-12.61%
3 months-26.63%
6 months-29.97%
Current year-56.24%
1 week 6.17
Extreme 6.17
7.03
1 month 6.17
Extreme 6.17
7.05
Current year 6.17
Extreme 6.17
14.92
1 year 6.17
Extreme 6.17
18
3 years 6.17
Extreme 6.17
39.4
5 years 6.17
Extreme 6.17
43.65
10 years 6.17
Extreme 6.17
89.68
Manager TitleAgeSince
Chief Executive Officer - 2026-02-01
Chief Executive Officer - 2025-09-21
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 44 2015-05-28
Director/Board Member 50 2017-05-18
Director/Board Member 52 2023-11-21
Change 5-day change 1-year change 3-year change Capi.($)
-3.59%-5.80% - - 94.84M
+3.35%+0.26%+24.56%+34.69% 242B
+3.34%-1.46%+2.89%+2.38% 150B
+3.71%+0.32%-10.14%+40.03% 138B
-0.47%-3.46%-56.43%-17.75% 61.74B
+2.44%+1.09%+13.18%+22.39% 49.08B
-1.08%-0.90%-21.39%-22.66% 47.43B
+2.09%-0.87%+20.93%+53.39% 47.3B
+3.70%+0.99%-4.33%+41.39% 44.25B
+3.51%+1.52%+34.02%+64.37% 41.78B
Average +1.49%-2.50%+0.37%+24.25% 91.4B
Weighted average by Cap. +2.36%-2.98%+4.07%+24.65%

Financials

2026 *2027 *
Net sales 764M 857M 712M 648M 1.22B 82.56B 1.23B 8.6B 3.34B 42.1B 3.22B 3.15B 135B 798M 896M 744M 677M 1.28B 86.28B 1.28B 8.99B 3.49B 44B 3.36B 3.29B 141B
Net income -35.8M -40.17M -33.37M -30.38M -57.26M -3.87B -57.62M -403M -157M -1.97B -151M -148M -6.34B 8.3M 9.31M 7.74M 7.04M 13.28M 897M 13.36M 93.47M 36.34M 457M 34.96M 34.2M 1.47B
Net Debt 376M 421M 350M 319M 601M 40.6B 605M 4.23B 1.64B 20.7B 1.58B 1.55B 66.54B 370M 416M 345M 314M 592M 40.03B 596M 4.17B 1.62B 20.41B 1.56B 1.53B 65.61B
Logo Guerbet
Guerbet is a European leader in producing and selling contrast products for medical imaging. The group's products make it possible to visualize different organs and the lymphatic and vascular systems of the human body by making them opaque. Net sales break down by product family as follows: - X-ray imaging products (54.4%); - MRI products (32.1%); - other (13.5%): contrast products for echography and nuclear medicine, fine chemicals products. At the end of 2024 the group had 8 production sites located in France (4), the United States (2), Ireland and Brazil. Net sales are distributed geographically as follows: Europe/Middle East/Africa (43.8%), Americas (29.7%) and Asia (26.5%).
Employees
2,700
Date Price Change
26-10-05 €6.170 -3.59%
26-10-02 €6.400 -3.76%
26-10-01 €6.650 -5.41%
26-09-30 €7.030 +7.33%
26-09-29 €6.550 -0.46%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
3
Last Close Price
6.650EUR
Average target price
8.433EUR
Spread / Average Target
+26.82%

Quarterly revenue - Rate of surprise